Welcome to our dedicated page for THERMO FISHER SCIENTIFIC SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on THERMO FISHER SCIENTIFIC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into THERMO FISHER SCIENTIFIC's regulatory disclosures and financial reporting.
Thermo Fisher Scientific Inc. Chairman & CEO Marc N. Casper reported option exercises and related share sales in company stock. On March 3 and 4, 2026, he exercised stock options for a total of 10,000 shares of Common Stock at a reported exercise price of $309.63 per share in multiple transactions coded as derivative exercises.
Over the same two days, Casper sold 10,000 shares of Common Stock in a series of open-market transactions, with prices reported around $495.29–$517.05 per share as weighted-average prices across multiple trades. The transactions were effected under a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, he directly held 123,925.358 shares of Common Stock and 44,550 stock options. Additional shares are held indirectly through the Alison Casper 2020 Irrevocable Trust, the MNC 2020 Irrevocable Trust, and Floral Park Associates, Inc., for which he disclaims beneficial ownership except for any pecuniary interest.
TMO files a Rule 144 notice reporting a proposed cash sale of 4,000 common shares on 03/05/2026.
The filing lists the securities as options granted on 02/25/2020 and identifies the sale method as cash. The excerpt also shows prior reported sales by Marc N. Casper: 5,000 shares on 03/03/2026 and 5,000 shares on 03/04/2026.
Marc Casper reported the sale of 5,000 common shares of TMO. The filing shows a sale dated 03/03/2026 with aggregate proceeds of $2,507,550.00 and a separate planned sale entry of 5,000 shares on 03/04/2026 tied to an option granted 02/25/2020.
Brokerage details list Fidelity Brokerage Services LLC and the transaction type is listed as Cash. The filing is a Form 144 disclosure of insider sales under the issuer symbol TMO.
Filer submitted a Form 144 notice to sell Common stock of the issuer (symbol TMO). The filing lists multiple restricted stock vesting lots and share counts by vesting date, including 980 shares vesting 02/23/2024, 955 shares vesting 02/28/2024, and other lots of 776, 705, 577, 434, 389, 233, 123, and 52 shares on various dates. The listed broker is Fidelity Brokerage Services LLC.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper reported two tax-withholding dispositions of common stock on February 28, 2026. He delivered 3,473.759 shares and 1,211.168 shares at $521.11 per share to cover tax liabilities, rather than executing open-market sales. Following these dispositions, he directly held 123,925.358 common shares. Additional common shares are held indirectly by the Alison Casper 2020 Irrevocable Trust, the MNC 2020 Irrevocable Trust, and Floral Park Associates, Inc., for which he disclaims beneficial ownership except to any pecuniary interest.
Thermo Fisher Scientific senior vice president and chief HR officer Lisa P. Britt reported two tax-withholding share dispositions. She transferred 262.6700 and 85.4090 shares of common stock at $521.1100 per share to cover tax liabilities. After these transactions, she directly owned 14,784.1480 common shares.
Thermo Fisher Scientific executive Joseph R. Holmes, VP & Chief Accounting Officer, reported several small dispositions of common stock on February 28, 2026. The transactions used code F, meaning shares were withheld to cover tax liabilities rather than sold in open-market trades. Blocks of stock were withheld at $521.11 per share, including 55.475 and 44.459 shares. After these tax-withholding dispositions, Holmes directly held about 2,966.3555 shares of Thermo Fisher common stock.
Thermo Fisher Scientific Executive Vice President Michel Lagarde reported two tax-withholding dispositions of common stock. On February 28, 2026, he delivered 836.8800 shares and 359.7250 shares of Thermo Fisher common stock at $521.1100 per share to cover tax obligations.
Thermo Fisher Scientific President & COO Gianluca Pettiti reported two tax-withholding dispositions of common stock under a Form 4. On February 28, 2026, he surrendered 741.7100 and 331.6810 shares at $521.11 per share to cover tax obligations, and directly owned 25,450.8320 shares afterward.